top of page
Browse by category
Search


Amylyx Pharmaceuticals LUCIDITY trial met its prespecified primary endpoint
Amylyx Pharmaceuticals has presented results from the 16-week double-blind treatment period of the Phase 3 LUCIDITY clinical trial of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, in participants with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB) surgery, at the ObesityWeek 2026 Annual Meeting. LUCIDITY met its prespecified primary endpoint, demonstrating a 55% reduction in the composite rate o


LUCIDITY: Avexitide reduce level 2 and 3 hypoglycaemic events by 55%
Amylyx Pharmaceuticals has announced positive topline results from LUCIDITY, a 78-participant, multi-centre, randomised, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, in participants with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB) surgery. LUCIDITY met the FDA-agreed-upon primary endpoint demonstrat
Browse by tag






bottom of page
